FAQ on Clene Inc.'s Participation in the D. Boral Capital Global Conference

What is the main topic of the press release?

The press release announces Clene Inc.’s participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, where its CEO will be available for one-on-one meetings.

Why is Clene Inc.’s participation in the conference significant?

This participation is significant as it provides an opportunity for Clene Inc. to showcase its focus on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, potentially attracting investors and partners.

How can interested parties schedule a one-on-one meeting with Clene Inc.’s CEO?

Interested parties can schedule one-on-one meetings with CEO Rob Etherington during the conference hours from 9 a.m. to 3 p.m. ET at The Plaza Hotel in New York City.

What is CNM-Au8® and what does it target?

CNM-Au8® is an investigational first-in-class therapy by Clene Nanomedicine Inc. that improves central nervous system cells’ survival and function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress.

Where can I find more information about Clene Inc.?

More information about Clene Inc. can be found on their official website at www.Clene.com or in the company’s newsroom at https://ibn.fm/CLNN.

What are the neurodegenerative diseases Clene Inc. is focused on treating?

Clene Inc. is focused on treating neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.

When and where is the D. Boral Capital Inaugural Global Conference taking place?

The conference is scheduled for May 14, 2025, at The Plaza Hotel in New York City.

Who is representing Clene Inc. at the conference?

Clene Inc.’s President and CEO, Rob Etherington, will be representing the company at the conference.

What is the purpose of InvestorWire in relation to this press release?

InvestorWire serves as a specialized communications platform for press release syndication, helping Clene Inc. reach a wide audience of investors, influencers, and the general public.